Viehbacher Exits Sanofi
Christopher A. Viehbacher resigned as director of Sanofi immediately after its Board of Directors unanimously agreed to remove him as the company’s CEO yesterday. Chairman Serge Weinberg will replace...
View ArticleSo Who’s in Charge of Medicines in Brussels?
So now we know who is to do what on health issues in the new European Commission. Or do we? The furor that the new boss of the commission, Jean-Claude Juncker, unleashed with the plans for his new...
View ArticleIsrael Set for “Modest” Pharma Growth
Israel’s pharmaceutical market value will increase from approximately $1.9 billion in 2013 to $2.34 billion, a compound annual growth rate of 2.8%, by 2020, says UK research and consulting firm...
View ArticleMeeting Patient-Centered Expectations in Europe
By Peter O’Donnell, Applied Clinical Trials. The growing insistence on making healthcare more patient-centered — Europe is currently awash with declarations of intent along those lines — is generating...
View ArticleGermany Post AMNOG
While emerging markets continue to represent a new channel of demand for pharmaceutical products, manufacturers have quickly realized that significant attention must still be given to more established...
View ArticleEMA States Position on Confidential Information
In response to a letter the European Medicines Agency received from the European Ombudsman on Oct. 27, 2014, the agency is clarifying its policy on commercially confidential information. EMA states in...
View ArticleNo-One's in Charge of Pharmaceuticals in Europe!
Peter O’Donnell’s recent Applied Clinical Trials blog, ‘Who’s in charge of Medicines in Brussels?‘, has been overtaken by history, with the departure of Guido Rasi from his post of Executive Director...
View ArticleEMA Revises Conflict-of-Interest Policy
The European Medicines Agency (EMA) has published its revised policy on handling declarations of interests for scientific-committee members and experts. The revisions strive for a more balanced...
View ArticleThe Year of Living Openly: Europe and Transparency 2015
The past year has brought significant changes not only in regulatory mandates and guidances but also regarding a broader overall emphasis on coordination of information and processes. The regulators...
View ArticleUK: Saatchi Innovation Bill Still Divisive
The innovation debate (Why isn’t there more or it? How much should we pay for it? Just what is it anyway?!) remains a lively one in the UK. Lord Saatchi’s Medical Innovation Bill is just one part of...
View Article
